Protagonist Therapeutics (MEX:PTGX) Total Stockholders Equity: MXN14,684 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:PTGX Protagonist Therapeutics Inc MEX:PTGX
53 GF Score
Price MXN1,565.33
GF Value MXN1,031.76
! 6 Warning Signs
View Full Analysis

What is Protagonist Therapeutics Total Stockholders Equity?

Protagonist Therapeutics MEX:PTGX 53 Total Stockholders Equity is MXN14,684 Mil as of Jun. 2026. GuruFocus rates MEX:PTGX with a GF Score™ of 53/100 and a GF Value™ of MXN1,031.76. The stock has 6 warning signs investors should review.

Protagonist Therapeutics's Total Stockholders Equity for the quarter that ended in Jun. 2026 was MXN14,684 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Protagonist Therapeutics's Book Value per Share for the quarter that ended in Jun. 2026 was MXN227.05. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Protagonist Therapeutics's Debt-to-Equity for the quarter that ended in Jun. 2026 was 0.01.

Protagonist Therapeutics  (MEX:PTGX) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Protagonist Therapeutics's Book Value per Share for the quarter that ended in Jun. 2026 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(14684.084-0)/64.672
=227.05

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Protagonist Therapeutics's Debt-to-Equity for the quarter that ended in Jun. 2026 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(41.808 + 119.002) / 14684.084
=0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Protagonist Therapeutics Total Stockholders Equity Related Terms

Protagonist Therapeutics Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Protagonist Therapeutics's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Protagonist Therapeutics Total Stockholders Equity Chart

Protagonist Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6,154.63 4,203.49 5,714.84 14,083.75 11,068.23

Protagonist Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12,578.25 11,840.03 11,068.23 11,819.95 14,684.08
MEX:PTGX
53GF Score
Protagonist Therapeutics Inc MEX:PTGX
Total Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Total Stockholders Equity of MXN14,684 Mil mean?
Protagonist Therapeutics (MEX:PTGX) has a Total Stockholders Equity of MXN14,684 Mil as of Jun. 2026. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Protagonist Therapeutics and its competitors.
Is Protagonist Therapeutics' Total Stockholders Equity too high?
Protagonist Therapeutics' current Total Stockholders Equity is MXN14,684 Mil. Overall, Protagonist Therapeutics has a GF Score™ of 53/100, reflecting its overall financial health beyond just this single metric.
How does Protagonist Therapeutics' Total Stockholders Equity compare to PRAX and CRNX?
Protagonist Therapeutics' Total Stockholders Equity of MXN14,684 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Biotechnology company?
A good Total Stockholders Equity depends on the Biotechnology industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Protagonist Therapeutics and its competitors. Protagonist Therapeutics's current Total Stockholders Equity is MXN14,684 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Protagonist Therapeutics stock overvalued right now?
Protagonist Therapeutics (MEX:PTGX) has a current Total Stockholders Equity of MXN14,684 Mil. The stock's GF Value™ is MXN1,031.76, compared to a current price of MXN1,565.33 — trading 51.7% above its estimated fair value. The current Total Stockholders Equity is MXN14,684 Mil. Protagonist Therapeutics' overall GF Score™ is 53/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For Protagonist Therapeutics (MEX:PTGX), the current Total Stockholders Equity is MXN14,684 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Protagonist Therapeutics (MEX:PTGX) Overvalued in 2026?

Based on GuruFocus' analysis, Protagonist Therapeutics stock appears to be overvalued. The current stock price of MXN1,565.33 is trading 51.7% above its estimated GF Value™ of MXN1,031.76.

Key valuation signals for MEX:PTGX:

  • Total Stockholders Equity: MXN14,684 Mil
  • GF Value™: MXN1,031.76 vs. price of MXN1,565.33 (51.7% above fair value)
  • GF Score™: 53/100 with 6 warning signs

No single metric tells the full story. See the MEX:PTGX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Protagonist Therapeutics Business Description

Other Exchanges PTGX:USA
Address 7707 Gateway Boulevard, Suite 140, Newark, CA, USA, 94560
Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.
53GF Score

Get the complete analysis for MEX:PTGX

Total Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN1,565.33
Price
MXN1,031.76
GF Value